- Home
- BRBR vs CORT Comparison
BRBR vs CORT Comparison
Compare BRBR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRBR | CORT |
|---|---|---|
| Founded | 2019 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 2019 | 2001 |
Fundamental Metrics
Financial Performance| Metric | BRBR | CORT |
|---|---|---|
| Price | $16.97 | $32.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 6 |
| Target Price | $43.56 | ★ $105.20 |
| AVG Volume (30 Days) | ★ 2.9M | 1.7M |
| Earning Date | 05-05-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.36 | ★ 0.82 |
| Revenue | ★ $2,316,600,000.00 | $761,407,000.00 |
| Revenue This Year | $6.36 | $29.97 |
| Revenue Next Year | $6.05 | $30.25 |
| P/E Ratio | $48.94 | ★ $41.10 |
| Revenue Growth | ★ 16.05 | 12.79 |
| 52 Week Low | $16.05 | $28.66 |
| 52 Week High | $79.57 | $117.33 |
Technical Indicators
Market Signals| Indicator | BRBR | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 34.98 | 30.90 |
| Support Level | N/A | $28.66 |
| Resistance Level | $19.35 | $41.92 |
| Average True Range (ATR) | 0.97 | 1.65 |
| MACD | 0.17 | 0.18 |
| Stochastic Oscillator | 22.38 | 8.07 |
Price Performance
Historical ComparisonAbout BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channel including club, food, drug and mass, eCommerce, convenience and specialty.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.